Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Annayyaon Mar 30, 2021 1:39pm
150 Views
Post# 32906851

RE:Green on a red day

RE:Green on a red day It is interesting that they delayed the earnings so I am hoping for good news as well, but generally the earnings don't move the share price much as the information is mostly financial related with a net loss reported as always. Maybe they will put out a new corporate update with updated info on progress. The estimated earnings for Q4 2020 is on March 31st. 

Past few years, it was reported on mid March.
https://www.marketbeat.com/stocks/TSE/PMN/earnings/

Thenorth1990 wrote: Even on a red day we are green, I guess the last time we were close to clinical trials this had gone 50 cents may be in 2017 to 2018. I really hope we have some surprise earnings to report, they haven't put it out there yet. Generally they post by the 2nd week.


<< Previous
Bullboard Posts
Next >>